(Q45954775)

http://europepmc.org/abstract/MED/26432951

18 December 2017

title

Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium. (English)

1 reference

http://europepmc.org/abstract/MED/26432951

18 December 2017

author

David A Griffith

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Markus Wallner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Ewald Kolesnik

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Senka Ljubojevic-Holzer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Brent Kuzmiski

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Klemens Ablasser

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Mounir Khafaga

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Paulina Wakula

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Eva Maria Thon-Gutschi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Harald Sourij

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Martin Kapl

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Nicholas J Edmunds

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Igor Knez

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Dirk von Lewinski

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Burkert Pieske

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

30 September 2015

1 reference

http://europepmc.org/abstract/MED/26432951

18 December 2017

published in

Journal of Molecular and Cellular Cardiology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

Pt B

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

365-375

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Diabetes in heart failure: prevalence and impact on outcome in the population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Epac proteins: multi-purpose cAMP targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

beta-Arrestin-dependent activation of Ca(2+)/calmodulin kinase II after beta(1)-adrenergic receptor stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Troglitazone stimulates beta-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

β-Arrestin2 plays a key role in the modulation of the pancreatic beta cell mass in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Calcium cycling and signaling in cardiac myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Functional effects of glucose transporters in human ventricular myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Levosimendan improves diastolic and systolic function in failing human myocardium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Population pharmacokinetics of levosimendan in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Atrial fibrillation in heart failure: a comprehensive review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Phosphorylation and desensitization of the human beta 1-adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

The cAMP binding protein Epac regulates cardiac myofilament function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

Initial steps of insulin signaling and glucose transport are defective in the type 2 diabetic rat heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2015.09.018

10.1016/J.YJMCC.2015.09.018

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26432951%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference